Molecular mechanisms of antibody-mediated immunotherapies

抗体介导的免疫疗法的分子机制

• 批准号: 8940844
• 负责人: JEFFREY Victor RAVETCH
• 金额: $ 101.7万
• 依托单位: ROCKEFELLER UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2016
• 资助国家: 美国
• 起止时间: 2016-04-01 至 2023-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8940844
• 关键词: Antibodies; Clinical; Disease; Generations; Goals; Immune response; Immune system; Immunotherapeutic agent; Immunotherapy; Lead; Malignant Neoplasms; Mediating; Memory; Modality; Molecular; Monoclonal Antibodies; Pathway interactions; Recurrence; Refractory; Therapeutic; Therapeutic Agents; Therapeutic Effect; Tumor Antibodies; Vaccination; base; fighting; improved; long term memory; neoplasm immunotherapy; neoplastic cell; public health relevance; response; tumor; tumor microenvironment

 DESCRIPTION (provided by applicant): Our studies over the past two decades have focused on clarifying the mechanisms by which anti-tumor immunotherapies elicit their therapeutic effects. As a result of our studies, the importance of Fc-FcγR mediated effector pathways for the elimination of tumors has been elucidated, resulting in the optimization of these interactions in second-generation anti-tumor immunotherapeutics with improved clinical activity. While these strategies have resulted in more effective anti-tumor antibodies (Abs) with significantly improved survival, the long-term goal of immunotherapy is to develop therapeutic strategies that will elicit memory responses that will effectively eliminate recurrences and thus result in long-term survival. This current proposal aims to mechanistically investigate general strategies to accomplish this goal by focusing on 1) inducing tumor vaccination using anti-tumor monoclonal Abs (mAbs), 2) define the mechanisms by which agonistic and antagonistic immunomodulatory mAbs enhance anti-tumor vaccination, and 3) explore how the tumor microenvironment may be manipulated in order to augment these immunotherapeutic strategies. Our preliminary results have indicated that anti-tumor Abs can elicit long-term cellular memory responses when appropriate Fc-FcγR interactions are integrated into these Abs. Manipulating both the cellular effector responses and the tumor microenvironment through the use of Fc-optimized immunomodulatory Abs can augment these pathways to result in long-term memory responses.

 描述（由适用提供）：在过去的二十年中，我们的研究重点是阐明抗肿瘤免疫疗法引起其治疗作用的机制。由于我们的研究，已经阐明了FC-FCγR介导的效应途径对消除肿瘤的重要性，从而在第二代抗肿瘤免疫治疗药中优化了这些相互作用，并改善了临床活性。尽管这些策略导致更有效的抗肿瘤抗体（ABS）具有显着提高生存率，但免疫疗法的长期目标是制定理论策略，以引起理论策略 记忆反应将有效消除回报，从而导致长期生存。目前的这项建议旨在通过重点关注1）使用抗肿瘤单克隆ABS（mAbs）的诱导肿瘤疫苗来机械地调查一般策略来实现这一目标策略。我们的初步结果表明，当适当的FC-FCγR相互作用整合到这些ABS中时，抗肿瘤ABS会引起长期的细胞记忆反应。通过使用FC优化的免疫调节性ABS来操纵细胞效应子的反应和肿瘤微环境，可以增强这些途径，从而产生长期的记忆反应。